CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $81.7273.
Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of CG Oncology in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research report on Monday, April 20th. Wedbush upped their price target on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Truist Financial reissued a “buy” rating and set a $82.00 price target (up from $77.00) on shares of CG Oncology in a research report on Thursday. Finally, Royal Bank Of Canada upped their price target on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 11th.
View Our Latest Report on CGON
CG Oncology Stock Down 6.0%
CG Oncology (NASDAQ:CGON – Get Free Report) last announced its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The business had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. On average, equities analysts expect that CG Oncology will post -2.89 earnings per share for the current fiscal year.
Insider Activity
In related news, Director James Mulay sold 15,600 shares of the company’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the sale, the director directly owned 15,600 shares of the company’s stock, valued at approximately $1,138,956. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.80% of the company’s stock.
Institutional Investors Weigh In On CG Oncology
Several institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System raised its position in shares of CG Oncology by 23.6% during the 1st quarter. California State Teachers Retirement System now owns 51,499 shares of the company’s stock valued at $3,485,000 after acquiring an additional 9,841 shares in the last quarter. Royal Bank of Canada raised its position in shares of CG Oncology by 18.6% during the 1st quarter. Royal Bank of Canada now owns 11,439 shares of the company’s stock valued at $774,000 after acquiring an additional 1,793 shares in the last quarter. EcoR1 Capital LLC grew its stake in CG Oncology by 3.5% during the 1st quarter. EcoR1 Capital LLC now owns 1,102,000 shares of the company’s stock worth $74,583,000 after buying an additional 37,200 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in CG Oncology by 6.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 136,544 shares of the company’s stock worth $9,241,000 after buying an additional 8,066 shares during the last quarter. Finally, Quantinno Capital Management LP bought a new position in CG Oncology during the 1st quarter worth $338,000. 26.56% of the stock is owned by institutional investors and hedge funds.
About CG Oncology
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Featured Stories
- Five stocks we like better than CG Oncology
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
